Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040170 · ClinicalTrials.gov registry record · Phase 2
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
A Phase 2 study, sponsored by Transgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00040170: Clinical Trial Phase 2 study, sponsored by Transgene.
NCT00040170 is a Phase 2 study that was terminated before completion, run by Transgene. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040170, a Phase 2 study, was terminated before completion, sponsored by Transgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
Interventions
- BIOLOGICAL MVA-MUC1-IL2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-05 |
| Phase | Phase 2 |
Why NCT00040170 stopped before completion
NCT00040170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which MVA-MUC1-IL2 is the first listed.
NCT00040170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040170 about?
NCT00040170 is a clinical study titled "Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer". This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
What is the current status of trial NCT00040170?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-05.
What interventions are being tested in trial NCT00040170?
The interventions under investigation include: MVA-MUC1-IL2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00040170?
This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00040170's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia